Yuichi Mikamoto

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 926 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura et al. · The Lancet Oncology · 2020 · 270 citations

Medicine, Oncology, Pharmacology +14

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2019 · 69 citations

Medicine, Oncology, Pharmacology +16

Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).

Kohei Shitara, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 10 citations

Pharmacy, Pharmacology, Cancer Drug Toxicity Management +9

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

Eiji Shinozaki, Akihito Kawazoe, Yasutoshi Kuboki et al. · Journal of Clinical Oncology · 2018 · 10 citations

Medicine, Oncology, Pharmacology +17